11 results about "Oxidative injury" patented technology

Compositions for the treatment of acute manifestations because of oxidative injury by reactive oxygen species (ROS) and chronic development of fibrosis are provided. Compositions of the present invention include perfluorocarbon, hydrogen and oxygen gas, N-acetylcysteine, and glycine to counter robust oxidative responses unleashed following injury from both mechanical and non-mechanical conditions. Methods are also disclosed for delivery to challenging locations (olfactory cleft, spinal canal) and in hostile conditions (post trauma brain, spine, and upper and lower airways), with the invention's products "calming" inflamed tissue by neutralizing ROS in both acute and later complications. Active pharmaceutical ingredient(s) can also be employed to provide both acute and chronic benefit, and such active ingredients themselves can be augmented by the composition, enabling increased drug uptake and oxygenation. The present invention provides broad relief in many conditions for both human and companion subjects.

The application belongs to the field of nanomaterials and biotechnology, and particularly relates to application of non-ROS-dependent photoenzyme in photocatalysis and Nrf2 activation. The preparation method of the non-ROS-dependent photoenzyme is as follows: chloroauric acid is added into a mixed solution of 6-azido-2-thiothymine and sodium hydroxide, and the reaction is stirred at 25-30 DEG C to prepare nanometer photoenzyme; the molar ratio of 6-azido-2-thiothymine to chloroauric acid is (2.1-2.6):1. The non-ROS-dependent nanometer photoenzyme provided by the application has the advantages of simple and efficient synthesis method, ultrahigh photocatalytic activity, non-ROS-dependent catalytic mechanism, excellent biocompatibility, and the ability to realize intracellular light-controlled activation of Nrf2, and solves the problems of ROS-dependent oxidative damage, uncontrollable Nrf2 activation, and over-activation of signal pathways.

The invention relates to the technical field of nursing materials, and discloses eye washing liquid for relieving eye fatigue and a preparation method thereof.The eye washing liquid is prepared from trehalose, taurine, sodium gualenate, sodium hyaluronate, ergothioneine, vitamin B12, vitamin B6, xanthophyll, mint, a humectant, a bacteriostatic agent, a chelating agent, a pH regulator and deionized water. Through the synergistic effect of the first synergistic composition and the second synergistic composition, retina cell injury induced by blue light can be effectively repaired, the repairing effect is superior to that of simple addition of a single component, blue light oxidative injury is repaired through a multi-target synergistic mechanism, a three-layer structure of a tear film lipid layer, a water layer and a mucoprotein layer can be reconstructed, and the repairing effect is good. According to the present invention, the tearable film stability is significantly improved, the excellent protection and repair effect is provided, the compatibility of the components is good, the product stability is high, and the multiple effects of ocular surface cleaning, asthenopia relieving, conjunctival congestion reducing and blue light oxidation damage preventing are provided.

The invention discloses application of sodium butyrate in preparation of a medicine for preventing or treating sepsis-related acute kidney injury, and relates to the technical field of pharmacy. The invention relates to an application of sodium butyrate in preparation of a medicine for preventing or treating sepsis-related acute kidney injury. The invention finds and verifies that sodium butyrate improves the kidney function of sepsis-related acute kidney injury, alleviates cell inflammatory response and oxidative injury and inhibits ferroptosis. The sodium butyrate inhibits ferroptosis by increasing the expression of VDR and GPX4 proteins.

The invention discloses an anti-aging composition containing a retinol derivative as well as a preparation method and application of the anti-aging composition, and belongs to the technical field of pharmaceutical preparations. The anti-aging composition comprises the following components in percentage by weight: 15-22% of an oil phase; 10 to 15% of polyol; 7.5-12% of a compound emulsifier; 0.5 to 2% of a retinol derivative; and the balance of deionized water. Wherein the compound emulsifier is prepared from 2 to 4 percent of inulin stearyl carbamate, 5 to 7 percent of behenyl alcohol polyether and 0.5 to 1.0 percent of behentrimethylammonium methyl sulfate. Through optimization of an emulsifier system, the problems of low stability and low permeability of a retinol derivative are solved, in addition, on the basis of the components of the anti-aging composition, the following raw materials in percentage by weight are added: 0.5-1.5% of a flavonoid compound, 0.5-1.5% of an emulsifier, 0.5-1.5% of an antioxidant and the balance of water. 0.05 to 0.1 percent of EDTA (Ethylene Diamine Tetraacetic Acid)- 0.15 to 0.3 percent of phenoxyethanol; 0.05 to 0.2 percent of ethylhexylglycerin; the external repair preparation capable of specifically solving the problem of skin oxidative injury induced by ultraviolet rays is prepared and obtained, the formula is mild and stable, the preparation process is simple, and the application prospect is wide.

The invention relates to casein peptide hydrolysate and application thereof in preparation of drugs for preventing or treating nerve aging, and belongs to the technical field of biological medicines. The casein hydrolysate is obtained by fermenting a casein solution with the probiotic bifidobacterium longum BNCC 185354, and the obtained casein hydrolysate has superoxide anion free radical scavenging capacity, can prolong the telomere length of the hippocampus of a subacute aging model mouse and relieve DNA oxidative damage of the hippocampus of the mouse. The brand-new casein peptide with both brain-accessible activity and biological activity is further screened from casein hydrolysate, free radicals can be removed, nerve cell inflammation can be eliminated, and therefore nerve aging is delayed. The casein peptide and the casein hydrolysate provided by the invention can be applied to preparation of drugs for preventing and / or treating nerve aging, and have good application prospects.

The present application belongs to the technical field of pharmaceutical preparations, and particularly relates to application of cellular globin in preparation of a medicine for preventing and / or treating diabetes. The present application uses cellular globin for treating diabetes, especially type II diabetes. In the case of persistent hyperglycemia of diabetes, the content of cellular globin is increased to effectively eliminate the oxidative damage of various sugar metabolism byproducts to the body in various tissues and organs of the body, thereby slowing down the occurrence and development of complications caused by diabetes, which is specifically manifested in: reducing the content of blood sugar; reducing the content of total cholesterol; reducing the content of triglyceride; reducing the level of low-density lipoprotein; improving and restoring the normal morphological structure of pancreatic tissue; promoting the proliferation of islet beta cells; and promoting the secretion of insulin and glucagon of islets. In summary, the cellular globin can be used for treating diabetes.

The invention relates to the technical field of biological materials, in particular to a fluorescent probe for targeting mitochondrial G4DNA, a preparation method and fluorescence lifetime imaging application. The fluorescent probe for targeting mitochondrial G4DNA has membrane permeability, high light stability, mitochondrial targeting and selective recognition capability on mtDNA, especially mitochondrial G4 quadruplex (mtG4DNA), and can realize real-time analysis of mtDNA abundance, conformation and mtG4DNA dynamic change under the condition of no need of gene manipulation, fixation or amplification. Through combination of stimulated radiation depletion (STED) or structured illumination super-resolution imaging (SIM) and a fluorescence lifetime imaging microscope (FLIM), the probe can provide intensity and lifetime dual signals at the same time, accurately maps mtDNA aggregate remodeling, oxidative damage and three-dimensional spatial-temporal dynamics participated by a G4 structure, and can be used for detecting the fluorescence lifetime of the mtDNA aggregate. A universal and non-invasive imaging platform is provided for researching related mechanisms of mitochondrial dysfunction, senescence and neurodegenerative diseases (such as ALS).

The invention discloses an application of a Fe3O4 (at) ZIF-8 nano-enzyme in preparation of a medicine for treating myocardial injury, the Fe3O4 (at) ZIF-8 nano-enzyme is of a core-shell structure which takes Fe3O4 as a nano-enzyme and is externally coated with ZIF-8, the overall average particle size of the nano-enzyme is (12-22) nm, it can be ensured that the ultra-small nano-enzyme has good dispersity and myocardial tissue accessibility, and the nano-enzyme can be used as a medicine for treating myocardial injury. And a ZIF-8 shell layer is utilized to stabilize the enzyme-like activity of Fe3O4 and regulate and control the microenvironment, so that additional oxidative damage caused by free iron is reduced, and the material as a main body plays a multi-dimensional mechanism of oxidation resistance, inflammation resistance and mitochondria protection. According to the invention, the Fe3O4 ZIF-8 nano-enzyme is applied to drug-induced myocardial injury for the first time, and it is found that the nano-enzyme shows a remarkable heart protection effect. The Fe3O4 ZIF-8 nano-enzyme can be prepared on a large scale, is good in biocompatibility, and has a wide application prospect in drug cardiotoxicity intervention and other ROS / inflammation related heart diseases.

Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy / craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.